Moderna agreed to settle long‑running patent litigation over lipid nanoparticle (LNP) delivery technology with Roivant’s Genevant and Arbutus, paying $950 million upfront and up to $2.25 billion total under a settlement disclosed by the parties. The deal resolves U.S. and international suits tied to Spikevax and related mRNA vaccines, and grants Moderna a global nonexclusive license for certain infectious‑disease uses. Company statements framed the settlement as removing legacy uncertainty so Moderna can focus on its pipeline. Legal filings signal the matter could still involve an appeal on government‑contract immunity (Section 1498) that would affect contingent payments, but the immediate cash payment closes most active disputes across jurisdictions.